首頁 > 市場調查報告書 > 製藥

非專利藥生技仿製藥

市場調查報告書

商品編碼

1550602

Pegfilgrastim的全球市場：按產品、按應用、按給藥途徑、按分銷管道、按地區

Pegfilgrastim Biosimilars Market, By Product, By Application, By Route of Administration, By Distribution Channel, By Geography

出版日期: 2024年08月08日 | 出版商:

Coherent Market Insights | 英文 165 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計2024年全球Pegfilgrastim市場規模將達16.9億美元，2024年至2031年複合年成長率為8.9%，2031年將達30.7億美元。

報告範圍		報告詳情
基準年	2023年	2024年市場規模	16.9億美元
實際資料	2019-2023	預測期	2024-2031
預測 2024-2031 年複合年成長率：	8.90%	2031 年金額預測	30.7億美元

圖：2024 年Pegfilgrastim按地區分類的市場佔有率(%)

Pegfilgrastim是非Filgrastim的長效形式，可刺激骨髓產生更多的白血球。Pegfilgrastim生物相似藥是Pegfilgrastim的生技學名藥或後續生技藥品。Pegfilgrastim的生物相似藥製劑在安全性、純度或功效上不具臨床意義的差異。生物相似藥為創新生物製藥提供了一種經濟高效的替代品，並擴大了患者獲得重要藥物的機會。Pegfilgrastim生物相似藥世界的成長是由對負擔得起的治療方案的需求不斷成長和創新藥物的專利到期推動的，導致多種生物學名藥進入市場。

市場動態：

全球Pegfilgrastim市場成長的驅動力是全球癌症發生率的上升。人們對生物相似藥的認知不斷提高以及政府對降低治療成本的支持正在推動Pegfilgrastim生物相似藥的採用。與參考生技藥品相比，成本更低也推動了市場成長。然而，生物相似藥的核准存在嚴格的規定，這可能給市場參與企業帶來挑戰。授予參考藥物的資料獨佔權也減緩了生物相似藥的市場進入。此外，複雜的製造流程和對專業知識的需求可能會阻礙市場成長。各種核准的生物相似藥和新興市場的強大管道的存在可以為市場成長提供機會。

本研究的主要特點

本報告提供了全球Pegfilgrastim市場的詳細分析，包括市場規模（十億美元）和年複合成長率（CAGR%）。

它還揭示了各個細分市場的潛在商機，並說明了該市場有吸引力的投資提案矩陣。

它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。

根據公司亮點、產品系列、主要亮點、績效和策略等參數，包括全球Pegfilgrastim市場主要公司的概況。

主要企業包括 Amgen、AryoGen Pharmed、Coherus Biosciences、Mylan、Dr Reddy's Laboratories 和 Biocon。

本報告中的見解將幫助負責人和公司經營團隊就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。

Pegfilgrastim全球市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、分銷商、新進業者和財務分析師。

相關人員可以透過分析全球Pegfilgrastim市場時所使用的各種策略矩陣來促進決策。

公司簡介
- CoherusBioSciences
- Mylan NV
- Biocon
- Sandoz（a Novartis division）
- Pfizer Inc.
- Apotex Inc.
- Cinfa Biotech
- Gedeon Richter
- StadaArzneimittel AG
- Mundipharma
- Aurobindo Pharma
- Glenmark Pharmaceuticals
- Dr. Reddy's Laboratories
- Intas Pharmaceuticals
- Biocad
- Genor Biopharma
- Qilu Pharmaceutical
- Henlius Biotech

第11章分析師建議

命運之輪
分析師觀點
一致的機會圖

第12章調查方法

參考
調查方法

簡介目錄

Product Code: CMI7242

Global pegfilgrastim biosimilars market is estimated to be valued at USD 1.69 Bn in 2024 and is expected to reach USD 3.07 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.9% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2024:	US$ 1.69 Bn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2024 to 2031 CAGR:	8.90%	2031 Value Projection:	US$ 3.07 Bn

Figure. Pegfilgrastim Biosimilars Market Share (%), By Region 2024

Pegfilgrastim is a long-acting form of filgrastim that stimulates the bone marrow to produce more white blood cells. Pegfilgrastim biosimilars are follow-on biologics or subsequent entry biologics of pegfilgrastim. These biosimilars have no clinically meaningful differences in terms of safety, purity, and potency from the original version of pegfilgrastim, when administered at the same dose. Biosimilars provide a cost-effective alternative to innovative biologics and expand access to important medicines for patients. Global pegfilgrastim biosimilars growth is driven by increasing demand for affordable treatment options and the patent expiration of innovator drugs, thus, leading to market entry of multiple biosimilars.

Market Dynamics:

Global pegfilgrastim biosimilars market growth is driven rising prevalence of cancer cases globally. Growing awareness about biosimilar drugs and government thrust on increasing affordability of treatment have boosted adoption of pegfilgrastim biosimilars. Lower costs compared to reference biologics also drives the market growth. However, presence of stringent regulations for biosimilar approval can pose challenge for market players. Data exclusivity granted to reference drugs also delays market entry of biosimilars. Furthermore, complex production processes and the need for specialized expertise can hamper the market growth. Presence of strong pipeline with various biosimilar approvals and emerging markets can offer opportunities for market growth.

Key features of the study

This report provides in-depth analysis of the global pegfilgrastim biosimilars market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global pegfilgrastim biosimilars market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Amgen, AryoGen Pharmed, Coherus Biosciences, Mylan, Dr Reddy's Laboratories, and Biocon

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global pegfilgrastim biosimilars market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pegfilgrastim biosimilars market

Detailed Segmentation-

By Product
- Pegfilgrastim Biosimilars
- Pegfilgrastim Reference Product
By Application
- Oncology
- Chronic Neutropenia
- Stem Cell Transplantation
- Others
By Route of Administration
- Subcutaneous
- Intravenous
By Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- CoherusBioSciences
- Mylan N.V.
- Biocon
- Sandoz (a Novartis division)
- Pfizer Inc.
- Apotex Inc.
- Cinfa Biotech
- Gedeon Richter
- StadaArzneimittel AG
- Mundipharma
- Aurobindo Pharma
- Glenmark Pharmaceuticals
- Reddy's Laboratories
- Intas Pharmaceuticals
- Biocad
- Genor Biopharma
- Qilu Pharmaceutical
- Henlius Biotech

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Product
- Market Snapshot, By Application
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Scenario
Acquisitions and Partnerships Scenario
Funding and Investments
PEST Analysis
Porter's Analysis

4. Global Pegfilgrastim Biosimilars Market- Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the Market

5. Global Pegfilgrastim Biosimilars Market, By Product, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Pegfilgrastim Biosimilars
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Pegfilgrastim Reference Product
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Pegfilgrastim Biosimilars Market, By Application, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Oncology
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Chronic Neutropenia
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Stem Cell Transplantation
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Pegfilgrastim Biosimilars Market, By Route of Administration, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Subcutaneous
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Intravenous
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Cartridge
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Pegfilgrastim Biosimilars Market, By Distribution Channel, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

9. Global Pegfilgrastim Biosimilars Market, By Region, 2019 - 2031, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2020-2031
- Regional Trends
  - North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
  - Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
  - North Africa
  - Central Africa
  - South Africa

10. Competitive Landscape

Company Profiles
- CoherusBioSciences
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Mylan N.V.
- Biocon
- Sandoz (a Novartis division)
- Pfizer Inc.
- Apotex Inc.
- Cinfa Biotech
- Gedeon Richter
- StadaArzneimittel AG
- Mundipharma
- Aurobindo Pharma
- Glenmark Pharmaceuticals
- Dr. Reddy's Laboratories
- Intas Pharmaceuticals
- Biocad
- Genor Biopharma
- Qilu Pharmaceutical
- Henlius Biotech